In a drug discovery career spanning more than two decades, Alex Lugovskoy has seen a lot of antibodies come and go. The vast majority of them work by inhibiting a cellular function. Lugovskoy, now the ...
Joel Levinson was in his second year of architecture studies at the University of Pennsylvania when he overheard two students speaking as if they were up to no good. These being fellow building buffs, ...
Diagonal Therapeutics is taking shape, launching with $128 million and backed by the likes of BVF Partners, Atlas Venture and RA Capital to develop a pipeline of antibody agonists. The company will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback